Rowland & CO Investment Counsel Regeneron Pharmaceuticals, Inc. Call Options Transaction History
Rowland & CO Investment Counsel
- $486 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding REGN
# of Institutions
1,483Shares Held
85.7MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$7.45 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$7 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$6.86 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.01 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$3.84 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $88.8B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...